Fimlab Laboratories Ltd has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions. Aiforia Technologies Plc, August 1, 2024 at 09:00 am EEST -- Fimlab Laboratories Ltd has selected Aiforia...

Ibex: Results Published in the Journal Pathology Kameda Adopts Ibex's Galen Prostate and Galen Breast to Support Pathologists in Primary Diagnosis BOSTON and CHIBA, Japan, May 20, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex),...

Ibex: Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying...

ArteraAI: The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based...

Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors’ potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by...

Deep Bio: An artificial intelligence-based prostate cancer diagnosis aid developed by a Korean company has received marketing authorization from overseas regulators, attracting the industry’s attention. Deep Bio said Tuesday that its...